At the news
? NEUTRALIMPACT 4/10 8-K filed Feb 26, 2026 at 08:00 ET
Edgewise Therapeutics reported Q4 2025 financial results with a net loss of $50.2 million and $530.1 million in cash. The company highlighted near-term catalysts including upcoming data readouts for EDG-7500 in HCM (H1 2026), EDG-15400 in heart failure (H1 2026), and pivotal GRAND CANYON data for sevasemten in Becker muscular dystrophy (Q4 2026).
- Cash, cash equivalents and marketable securities: $530.1 million as of December 31, 2025
- R&D expenses: $43.6 million for Q4 2025 (up from $37.5 million in Q3)
- G&A expenses: $12.4 million for Q4 2025 (up from $9.4 million in Q3)
- Net loss: $50.2 million or $0.47 per share for Q4 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access